natgillin/translations-raw huggingface dataset:
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery .
U studiji CURE s klopidogrelom uz ASK nije bilo povećanog broja velikih krvarenja tijekom 7 dana nakon ugrađivanja srčane premosnice u bolesnika koji su lijekove prestali uzimati više od pet dana prije kirurškog zahvata.
In current clinical practice, whole blood levels are monitored using immunoassay methods.
U sadašnjoj se kliničkoj praksi razine u punoj krvi prate pomoću imunotestova.
In Cushing’s disease patients, pasireotide demonstrates linear and time-independent pharmacokinetics in the dose range of 0.3 mg to 1.2 mg twice a day.
U bolesnika s Cushingovom bolešću, pasireotid pokazuje linearnu farmakokinetiku ovisnu o vremenu u rasponu doza od 0,3 mg do 1,2 mg dvaput na dan.
In Cushing’s disease, the tumour causes overproduction of a hormone called ACTH, which in turn stimulates the production of too much cortisol (a hormone also known as the ‘stress hormone’ because it is released in response to stress).
U slučaju Cushingove bolesti, tumor uzrokuje prekomjernu proizvodnju hormona naziva ACTH, koji zatim stimulira stvaranje prevelike količine kortizola (hormona koji je također poznat pod nazivom „hormon stresa“ budući da se luči kao odgovor na stres).
In Cycle 1, the overall incidence of IRRs was higher in patients with Gazyvaro and bendamustine (G+B) (55%) compared to patients receiving B alone (42%) (with Grade 3-5 IRRs reported in 9% and 2%, respectively and no fatal events reported).
U 1. ciklusu je ukupna incidencija reakcija na infuziju bila veća u bolesnika liječenih lijekom Gazyvaro i bendamustinom (G+B) (55%) nego u onih koji su primali samo bendamustin (42%) (reakcije na infuziju 3. – 5. stupnja prijavljene su u 9% odnosno 2% bolesnika, ali nije prijavljen nijedan smrtni slučaj).
In cycles 1 and 2, Empliciti is administered once weekly on days 1, 8, 15, and 22.
U 1. i 2. ciklusu Empliciti se primjenjuje jedanput na tjedan, 1., 8., 15. i 22. dana.
In cycles 1 to 4, Bortezomib Accord is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Tijekom 1. do 4. ciklusa, Bortezomib Accord se primjenjuje dva puta tjedno (na 1., 4., 8., 11., 22., 25., 29. i 32. dan).
In cycles 1 to 4, bortezomib is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Tijekom 1. do 4. ciklusa, bortezomib se primjenjuje dva puta tjedno na 1., 4., 8., 11., 22., 25., 29. i 32. dan.
In Cycles 1-4, Bortezomib Hospira is administered twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32.
Tijekom 1. do 4. ciklusa, Bortezomib Hospira se primjenjuje dva puta tjedno, na 1., 4., 8., 11., 22., 25., 29. i 32. dan.
In cycles 3 and beyond, Empliciti is administered once every 2 weeks on days 1 and 15.
U 3. i svim sljedećim ciklusima Empliciti se primjenjuje jedanput svaka 2 tjedna, 1. i 15. dana.
In cycles 5 to 9, Bortezomib Accord is administered once weekly on days 1, 8, 22 and 29.
Tijekom 5. do 9. ciklusa, Bortezomib Accord se primjenjuje jednom tjedno (na 1., 8., 22. i 29. dan).
In cycles 5 to 9, bortezomib is administered once weekly on days 1, 8, 22 and 29.
Tijekom 5. do 9. ciklusa, bortezomib se primjenjuje jednom tjedno na 1., 8., 22. i 29. dan.
In cycles 5 to 9, Bortezomib SUN is administered once weekly on days 1, 8, 22 and 29.
Tijekom 5. do 9. ciklusa, Bortezomib SUN se primjenjuje jednom tjedno na 1., 8., 22. i 29. dan.
In cycles 5 to 9, VELCADE is administered once weekly on days 1, 8, 22 and 29.
Tijekom 5. do 9. ciklusa, VELCADE se primjenjuje jednom tjedno (na 1., 8., 22. i 29. dan).
In Cycles 5-9, Bortezomib Hospira is administered once weekly on days 1, 8, 22 and 29.
Od 5. do 9. ciklusa, Bortezomib Hospira se primjenjuje jednom tjedno, na 1., 8., 22. i 29. dan.
In CYP2D6 poor metabolisers, concomitant use of potent inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers.
U sporih CYP2D6 metabolizatora, istodobna uporaba jakih inhibitora CYP3A4 može rezultirati višim koncentracijama aripiprazola u plazmi u odnosu na one u brzih CYP2D6 metabolizatora.
In cystic fibrosis these secretions become thick and cause blockage.
Pri cističnoj fibrozi taj sekret postaje gust i uzrokuje začepljenja.
In cytopenic dogs, there were no adverse events on progenitor and proliferating cells in the bone marrow.
U pasa s citopenijom nije bilo štetnih događaja za matične i proliferacijske stanice koštane srži.
In cytopenic dogs, there were no adverse events on progenitor and proliferating cells in the bone marrow.
U pasa s citopenijom nije bilo štetnih učinaka na matične i proliferacijske stanice koštane srži.
In cytopenic dogs, there were no adverse events on progenitor and proliferating cells in the bone marrow.
U pasa s citopenijom nije bilo štetnih učinaka na matičnim i proliferacijskim stanicama koštane srži.
In cytopenic dogs, there were no undesirable effects on progenitor and proliferating cells in the bone marrow.
U pasa s citopenijom nije bilo štetnih učinaka za matične i proliferacijske stanice koštane srži.
In de novo kidney and liver transplant patients AUC0-24 of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for the immediate release capsules (Prograf at equivalent doses.
AUC0-24 takrolimusa iz Advagrafa u usporedbi s kapsulama s trenutnim oslobađanjem takrolimusa (Prograf) pri ekvivalentnim dozama bila je prvog dana 30% niža u bolesnika koji su de novo primili presadak bubrega i 50% niža u bolesnika koji su de novo primili presadak jetre.
In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents.
Prilikom odluke o početku liječenja Aptivusom, uz istodobnu primjenu niske doze ritonavira, potrebno je pažljivo razmotriti povijest liječenja pojedinog bolesnika te obrasce mutacija povezanih s različitim lijekovima.
In diabetic macular oedema, Lucentis was more effective at improving vision than its comparators.
Kod dijabetičkog makularnog edema Lucentis se pokazao djelotvornijim u poboljšavanju vida od ostalih usporednih lijekova.
In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.
U bolesnika sa šećernom bolešću može biti potrebna prilagodba doze inzulina ili peroralnih hipoglikemijskih lijekova.
In dialysis patients, Aranesp may continue to be administered as a single injection once weekly or once every two weeks.
U bolesnika na dijalizi može se nastaviti s primjenom Aranespa kao pojedinačne injekcije jednom tjedno ili jednom svaka 2 tjedna.
In dietary administration studies in which mice and rats were treated with propranolol hydrochloride for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis.
U studijama upravljanja prehranom u kojima su miševi i štakori liječeni propranololom hidrokloridom do 18 mjeseci, u dozama do 150 mg/kg/dnevno, nije bilo dokaza o tumorigenezi povezanoj s lijekom.
In direct comparison, requirements for bioequivalence are met for Tresiba 100 units/mL and Tresiba 200 units/mL (based on AUCIDeg,τ,SS and Cmax,IDeg,SS).
U neposrednoj usporedbi, zahtjevi bioekvivalencije su ispunjeni za lijek Tresiba 100 jedinica/ml i Tresiba 200 jedinica/ml (na temelju AUCIDeg,τ,SS i Cmax, IDeg,SS).
in disposable pen
primjenu
in disposable pen cartridge (glass)
napunjenoj brizgalici uložak (staklo) u
in disposable pen cartridge (glass)
napunjenoj brizgalici uložak (staklo) za
in disposable pens cartridge (glass)
napunjenoj brizgalici uložak (staklo) u
In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with increasing degrees of severity.
OHSS je medicinsko stanje koje se jasno razlikuje od nekompliciranog povećanja jajnika i koje se može manifestirati u rastućim stupnjevima težine.
in divided doses over 2 - 5 days in association with acetylsalicylic acid
u podijeljenim dozama kroz 2 - 5
in divided doses over 2 - 5 days in association with acetylsalicylic acid
u podijeljenim dozama kroz 2 - 5 dana,
in divided doses over 2 to 5 days in association with acetylsalicylic acid
u podijeljenim dozama tijekom 2 do 5 dana u kombinaciji s acetilsalicilatnom kiselinom
in divided doses over 2-5 days
u podijeljenim dozama kroz 2 - 5 dana
In Docetaxel Accord 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici Docetaxel Accord 160 mg/8 ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Accord 20 mg/1 ml vial the concentration of docetaxel is 20 mg/ml.
Kod bočica Docetaxel Accord od 20 mg/1 ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Accord 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici Docetaxel Accord 80 mg/4 ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Accord vial the concentration of docetaxel is 20 mg/ml.
U bočici DocetaxelAccord koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Winthrop 160 mg/8 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici Docetaxel Winthrop 160 mg/8 ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Winthrop 20 mg /1 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici Docetaxel Winthrop 20 mg/l ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Winthrop 20 mg/1 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici lijeka Docetaxel Winthrop 20 mg/1 ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Winthrop 80 mg /4 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici Docetaxel Winthrop 80 mg/4 ml, koncentracija docetaksela iznosi 20 mg/ml.
In Docetaxel Winthrop 80 mg/4 ml vial the concentration of docetaxel is 20 mg/ml.
U bočici Docetaxel Winthrop 80 mg/4 ml, koncentracija docetaksela iznosi 20 mg/ml.
In dogs and cats, occasional side effects of Metacam are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools, apathy (lack of vitality) and kidney failure.
U pasa i mačaka uočene su povremene nuspojave povezane s NSAID-ovima, poput gubitka apetita, povraćanja, proljeva, krvi koja se pojavljuje u stolici, apatije (gubitka vitalnosti) i zatajenja bubrega.
In dogs developing a leishmaniosis (active infection and/or disease) despite vaccination, proceeding with vaccine injections showed no benefit.
Kod pasa s kliničkim simptomima lišmanioze (aktivna infekcija i/ili bolest) unatoč vakcinaciji, nastavak davanja cjepiva nije davalo rezultata.
In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0  4.8 mol/l have been observed after 3 hours of anaesthesia.
U pasa izloženih koncentraciji sevoflurana od 4% tijekom 3 sata, prosječne vršne koncentracije fluorida primijećene u serumu iznosile su 20.0  4.8 mol/l nakon 3 sata anestezije.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7 – 18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.
U pasa koji su tijekom 6 do 12 mjeseci svakodnevno primali tadalafil u dozama od 25 mg/kg na dan (što je rezultiralo najmanje trostruko većom izloženošću [raspon 3,7-18,6 puta] od one u ljudi kod primjene jedne doze od 20 mg) i većima, zabilježena je regresija epitela sjemenovodnih kanalića, što je u nekih pasa dovelo do smanjene spermatogeneze.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7 – 18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.
U pasa koji su tijekom 6 do 12 mjeseci svakodnevno primali tadalafil u dozama od 25 mg/kg na dan (što je rezultiralo najmanje trrostruko većom izloženošću [raspon 3,7 – 18,6 puta] od one u ljudi kod primjene jedne doze od 20 mg) i većima, zabilježena je regresija epitela sjemenovodnih kanalića, što je u nekih pasa dovelo do smanjene spermatogeneze.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-–-18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.
U pasa koji su tijekom 6 do 12 mjeseci svakodnevno primali tadalafil u dozama od 25 mg/kg na dan (što je rezultiralo najmanje trrostruko većom izloženošću [raspon 3,7 – 18,6 puta] od one u ljudi kod primjene jedne doze od 20 mg) i većima, zabilježena je regresija epitela sjemenovodnih kanalića, što je u nekih pasa dovelo do smanjene spermatogeneze.
In dogs it is applied between the shoulder blades at the bottom of the dog’s head, but for large dogs (above 25 kg) the product should be applied in 3 or 4 spots along the dog’s back, whilst it is standing, from between its shoulder blades to the base of its tail.
U pasa se primjenjuje između lopatica na dnu glave, ali za veće pse (iznad 25 kg) proizvod treba primijeniti na 3 ili 4 mjesta duž leđa psa dok životinja stoji, od područja između lopatica do baze njegovog repa.
In dogs treated at the therapeutic dose for ten consecutive days, serum cortisol levels decreased from five days onward and returned to normal values within ten days after the end of treatment.
Vrijednosti kortizola u serumu vratile su se na normalne vrijednosti unutar 10 dana po prestanku primjene ovog VMP.
In dogs with non- resectable mast cell tumours, Grade 2 or 3, expressing a mutated tyrosine kinase c-kit receptor, treatment with Masivet showed a significantly longer Time-to-Tumour Progression (TTP) with a median of 241 days as compared to 83 days for placebo.
U pasa s neoperabilnim tumorom mastocita, 2. ili 3. stupnja s izraženim mutiranim receptorom, tirozin kinaze c-kit, liječenje Masivetom je značajno produžilo vrijeme do progresije tumora (Time-to-Tumour Progression - TTP) uz središnju vrijednosti od 241 dana u odnosu na 83 dana za placebo.
In dogs, a slight increase in resorptions was seen; however, all foetuses in medication–treated animals were viable, and the incidence of live foetuses in medication– treated animals was comparable to that in controls.
U pasa je uočeno blago povećanje resorpcije; međutim, svi fetusi u životinja koje su primale lijek bili su vijabilni, a incidencija živih fetusa u životinja koje su primale lijek bila je slična onoj u kontrolnoj skupini.
In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported.
Kod pasa su vrlo rijetko zabilježeni hemoragični proljev, hematemeza i gastrointestinalni ulkusi.
In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported.
U vrlo rijetkim slučajevima u pasa zabilježeni su proljev s krvarenjem, hematemeza i gastrointestinalne ulceracije.
In dogs, in very rare cases, haemorrhagic diarrhoea, haematemesis, and gastrointestinal ulceration have been reported.
U vrlo rijetkim slučajevima u pasa zabilježeni su proljev s krvarenjem, povraćanje krvi (hematemeza) i gastrointestinalne ulceracije.
In dogs, Inflacam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Inflacam se primjenjuje u pasa za ublažavanje postoperativnog bola i upale nakon ortopedskog zahvata (primjerice operacije frakture) i kirurškog zahvata na mekom tkivu.
In dogs, Metacam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Metacam se koristi kod pasa za ublažavanje postoperativne boli i upale nakon ortopedskog zahvata (primjerice operacije frakture) i kirurškog zahvata na mekanom tkivu.
In dogs, Rheumocam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Rheumocam se koristi kod pasa za ublažavanje postoperativne boli i upale nakon ortopedskog zahvata (primjerice operacije frakture) i kirurškog zahvata na mekanom tkivu.
In dogs, robenacoxib was in vitro approximately 140 fold selective for COX-2 (IC50 0.04 μM) as compared to COX-1 (IC50 7.9 μM).
U in vitro ispitivanjima pune krvi kod pasa, selektivnost robenakoksiba se pokazala približno 140 puta većom na COX-2 (IC50 0,04 μM) u usporedbi s COX-1 (IC50 7,9 μM).
In dogs, slight inflammatory responses were observed following chronic high dose administration of ambrisentan at exposures greater than 20–fold that observed in patients.
U pasa su zapaženi blagi upalni odgovori pri 20 puta većoj izloženosti od one u bolesnika.
In dogs, the heart was not affected by treatment, as no ECG changes were seen at different treatment times, nor heart changes were detected at gross- and histopathology.
U pasa, srce nije bilo pogođeno liječenjem, jer nisu zabilježene promjene u EKG-u snimanom u različitim vremenskim intervalima tijekom liječenja, niti su primijećene makro- i mikropatološke promjene na srcu.
In dogs, these adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
U pasa, ove nuspojave općenito se javljaju unutar prvog tjedna liječenja i u većini slučajeva su prolazne te nestaju nakon prekida liječenja, no u vrlo rijetkim slučajevima mogu biti ozbiljne ili fatalne.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
U pasa, te se nuspojave obično javljaju tijekom prvog tjedna liječenja i u većini su slučajeva prolazne te nestaju nakon prestanka liječenja, ali u vrlo rijetkim slučajevima mogu biti ozbiljne ili smrtonosne.
In dogs, these side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.
U pasa, te se nuspojave obično javljaju tijekom prvog tjedna liječenja i u većini su slučajeva prolazne te nestaju nakon prestanka liječenja, ali u vrlo rijetkim slučajevima mogu biti ozbiljne ili smrtonosne.
In dogs, when cefovecin was administered as a single subcutaneous dose of 8 mg/kg bodyweight, absorption was rapid and extensive; peak plasma concentration at 6 hours was 120 g/ml and bioavailability approximately 99 %.
Kada je cefovecin primijenjen kao pojedinačna subkutana doza od 8 mg/kg tjelesne težine u pasa, apsorpcija je bila rapidna i ekstenzivna; najviša koncentracija u plazmi nakon 6 sati bila je 120 g/ml, a bioraspoloživost približno 99%.
In dogs:
Kod pasa:
In dogs: Moderate swelling at the implant site may be observed for 14 days.
Psi: Na mjestu implantacije može se javiti oteklina umjerenog intenziteta koja može potrajati 14 dana.
In dose escalation studies, Odomzo was administered at doses up to 3000 mg orally once daily.
U ispitivanjima postupnog povećavanja doze Odomzo se primjenjivao u dozama do 3000 mg peroralno jedanput na dan.
In dose-finding trials involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose limiting toxicity of topotecan monotherapy was found to be haematological.
U ispitivanjima u kojima se utvrđuje doza lijeka, provedenim u 523 bolesnice s recidivom karcinoma jajnika i 631 bolesniku s recidivom karcinoma pluća malih stanica, hematotoksičnost se pokazala čimbenikom ograničenja doze u monoterapiji topotekanom.
In dose-finding trials involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose limiting toxicity of topotecan monotherapy was found to be haematological.
U ispitivanjima u kojima se utvrđuje doza lijeka, provedenima u 523 bolesnice s recidivom karcinoma jajnika i 631 bolesniku s recidivom karcinoma pluća malih stanica, hematotoksičnost se pokazala čimbenikom ograničenja doze u monoterapiji topotekanom.
In dose-finding trials involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose limiting toxicity of topotecan monotherapy was found to be haematological.
U ispitivanjima u kojima se utvrđuje doza lijeka, provedenima u 523 bolesnice s recidivom raka jajnika i 631 bolesnika s recidivom raka pluća malih stanica, hematotoksičnost se pokazala čimbenikom ograničenja doze u monoterapiji topotekanom.
In doses of 1,400 to 2,000 mg per day, the following side effects are more common:
U dozama od 1400 do 2000 mg po danu, sljedeće nuspojave su češće:
In double blind and open-label clinical trials in 4,149 patients treated with intravenous abatacept during 11,584 patient-years, the incidence rate of serious infections was 2.87 per 100 patient -years, and the annualized incidence rate remained stable.
U dvostruko slijepim i otvorenim kliničkim ispitivanjima, u 4149 bolesnika liječenih abataceptom intravenski tijekom 11 584 bolesnik-godina stopa incidencije ozbiljnih infekcija iznosila je 2,87 na 100 bolesnik-godina te je ostala stabilna na godišnjoj razini.
In double blind and open-label clinical trials in 4,149 patients treated with intravenous abatacept during 11,932 patient-years (of which over 1,000 were treated with abatacept for over 5 years), the incidence rate of malignancy was 1.42 per 100 patient-years, and the annualized incidence rate remained stable.
U dvostruko slijepim i otvorenim kliničkim ispitivanjima, u 4149 bolesnika liječenih abataceptom intravenski tijekom 11 932 bolesnik-godine (od kojih je više od 1000 liječeno abataceptom dulje od 5 godina) incidencija zloćudnih bolesti bila je 1,42 na 100 bolesnik-godina te je ostala stabilna na godišnjoj razini.
In drinking water use
Za primjenu u vodi za piće
In drinking water use, nebulisation use, oculonasal use
intranazalno/ okularno, raspršivanjem ili u vodi za piće
In drinking water use, nebulisation use, oculonasal use
intranazalo/ okularno, raspršivanjem ili u vodi za piće
In drug-drug interaction studies in healthy male and female subjects, Fexeric decreased the bioavailability of concomitantly administered ciprofloxacin (as measured by the area under the curve [AUC]) by approximately 45%.
U ispitivanjima interakcija lijekova u zdravih muških i ženskih ispitanika, Fexeric je smanjio bioraspoloživost istodobno primijenjenog ciprofloksacina (mjereno površinom ispod krivulje [AUC]) za otprilike 45 %.
In DUET-1 and DUET-2, the presence at baseline of 3 or more of the following mutations: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A and G190S,
U ispitivanjima DUET-1 i DUET-2, prisutnost 3 ili više sljedećih mutacija: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A i G190S,
In DVT and PE treatment, patients receiving fondaparinux 5 mg (body weight <50 kg), 7.5 mg (body weight 50-100 kg inclusive) and 10 mg (body weight >100 kg) once daily, the body weight-adjusted doses provide similar exposure across all body weight categories.
U liječenju DVT i PE, u bolesnika koji su primali fondaparinuks u dozi od 5 mg (tjelesna težina <50 kg), 7,5 mg (tjelesna težina 50 – 100 kg) ili 10 mg (tjelesna težina >100 kg), doza prilagođena tjelesnoj težini omogućuje sličnu izloženost u svim težinskim kategorijama.
In each experiment, four groups of six ferrets were immunised intramuscularly with an AS03 adjuvanted vaccine containing HA derived from H5N1/A/Vietnam/1194/04 (NIBRG-14).
U svakom pokusu, četiri skupine po šest tvorova imunizirano je AS03-adjuvantiranim cjepivom koje sadrži 3,75 µg hemaglutinina dobivenog iz soja H5N1/A/Vietnam/1194/04 (NIBRG-14) intramuskularnim putem.